204 related articles for article (PubMed ID: 17088416)
1. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.
Catalano MG; Poli R; Pugliese M; Fortunati N; Boccuzzi G
Endocr Relat Cancer; 2007 Sep; 14(3):839-45. PubMed ID: 17914112
[TBL] [Abstract][Full Text] [Related]
3. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Kim TH; Yoo YH; Kang DY; Suh H; Park MK; Park KJ; Kim SH
Int J Oncol; 2009 May; 34(5):1353-62. PubMed ID: 19360347
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin induces apoptosis with profile of large-scale DNA fragmentation and without DNA ladder in anaplastic thyroid carcinoma cells via histone hyperacetylation.
Rho JH; Kang DY; Park KJ; Choi HJ; Lee HS; Yee SB; Yoo YH
Int J Oncol; 2005 Aug; 27(2):465-71. PubMed ID: 16010429
[TBL] [Abstract][Full Text] [Related]
5. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
Catalano MG; Pugliese M; Poli R; Bosco O; Bertieri R; Fortunati N; Boccuzzi G
Oncol Rep; 2009 Feb; 21(2):515-21. PubMed ID: 19148530
[TBL] [Abstract][Full Text] [Related]
6. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
Takai N; Kawamata N; Gui D; Said JW; Miyakawa I; Koeffler HP
Cancer; 2004 Dec; 101(12):2760-70. PubMed ID: 15536623
[TBL] [Abstract][Full Text] [Related]
7. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Mitsiades CS; Poulaki V; McMullan C; Negri J; Fanourakis G; Goudopoulou A; Richon VM; Marks PA; Mitsiades N
Clin Cancer Res; 2005 May; 11(10):3958-65. PubMed ID: 15897598
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
10. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
Ahn MY; Jung JH; Na YJ; Kim HS
Gynecol Oncol; 2008 Jan; 108(1):27-33. PubMed ID: 17920664
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.
Aouali N; Palissot V; El-Khoury V; Moussay E; Janji B; Pierson S; Brons NH; Kellner L; Bosseler M; Van Moer K; Berchem G
Br J Haematol; 2009 Dec; 147(5):662-71. PubMed ID: 19793255
[TBL] [Abstract][Full Text] [Related]
13. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
[TBL] [Abstract][Full Text] [Related]
14. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
Sasaki K; Yamagata T; Mitani K
Cancer Sci; 2008 Feb; 99(2):414-22. PubMed ID: 18271940
[TBL] [Abstract][Full Text] [Related]
16. Hepatoprotection and lethality rescue by histone deacetylase inhibitor valproic acid in fatal hemorrhagic shock.
Gonzales ER; Chen H; Munuve RM; Mehrani T; Nadel A; Koustova E
J Trauma; 2008 Sep; 65(3):554-65. PubMed ID: 18784568
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.
Dubois F; Caby S; Oger F; Cosseau C; Capron M; Grunau C; Dissous C; Pierce RJ
Mol Biochem Parasitol; 2009 Nov; 168(1):7-15. PubMed ID: 19538992
[TBL] [Abstract][Full Text] [Related]
18. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors as anti-neoplastic agents.
Batty N; Malouf GG; Issa JP
Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis.
Krämer OH; Knauer SK; Zimmermann D; Stauber RH; Heinzel T
Oncogene; 2008 Jan; 27(6):732-40. PubMed ID: 17653085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
